FDA Safety Flag
The FDA has identified this substance as one that may present significant safety risks when used in compounding, including concerns about immunogenicity, impurity characterization, and/or insufficient safety information.
WADA S2
This substance falls under WADA S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics). If you are subject to anti-doping rules, this category of substances is prohibited at all times.
GH Axis
This substance modulates the growth hormone axis. GH-axis stimulation carries risks including glucose intolerance, fluid retention, and theoretical concerns about sustained IGF-1 elevation.
Evidence visual
GHRP-6 evidence and risk matrix
intermediate researcher fit
Evidence
Tier B
Risk
high
Regulatory
not approved
WADA
S2
FDA
flagged
Route
intravenous
Higher-confidence evidence profile, but regulatory and sourcing checks still matter.
Overview
GHRP-6 is a GH-releasing peptide. Phase I PK work included escalating single IV bolus doses (100-400 µg/kg) in healthy volunteers. FDA flagged GHRP-6 for compounding safety concerns including immunogenicity/impurities and potential effects on cortisol and blood glucose via decreased insulin sensitivity. PK shows short distribution and hours-scale elimination.
Decision path
Where GHRP-6 fits in the research path.
Use the evidence and risk profile first, then compare vendors and run the quiz before turning this compound into a protocol decision.
01
Read evidence
02
Check risk
03
Compare options
04
Build plan
Peptide research path
Decide whether GHRP-6 belongs in your plan.
Use the quiz before choosing a compound, vendor, or PDF. It routes by goal, experience, budget, safety flags, and monitoring comfort.
Research Details
GH secretagogue stimulating GH release with smaller ACTH/PRL effects relative to other class members.
intravenous, subcutaneous
Human phase I: IV bolus 100-400 µg/kg; physiological studies: 1 µg/kg IV.
GH-axis stimulation; appetite stimulation commonly reported.
Acute GH response after IV dosing; PK shows hours-scale elimination.
No formal label.
Immunogenicity/impurity concerns (FDA); cortisol effects; decreased insulin sensitivity; glucose metabolism risk.
Flag glucose metabolism risk and endocrine-axis spillover as monitoring concerns.
Cost at a glance
Typical cycle cost
€35.76
Estimated monthly
€17.88
Protocol style
6-12 week phase
Phase-based
Estimate confidence
High confidence
Assumes roughly 12 mg–24 mg per cycle, using 1 tracked affiliated listing.
Appetite-led use often carries meaningful total volume across an 8-week phase.
Known Interactions
Additive GH-axis stimulation plausible; FDA flags both compounds in compounding safety-risk context.
GHRH analog + GHS-R agonist: additive GH release plausible.
Multiple GHS/GHS-R stimulation; FDA flags both for compounding risks/limited safety info.
Multiple GHS/GHS-R stimulation; higher uncertainty.
Redundant GHSR stimulation with added appetite and glucose-management downside.
Information provided for educational and research reference only. Not medical advice. Not for diagnosing, treating, curing, or preventing disease. Products referenced are labeled Research Use Only (RUO) by vendors; not for human or veterinary use.
Sources and review notes
- Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks - U.S. Food and Drug Administration - accessed 2026-05-15
Used for FDA compounding-risk context and peptide safety flags.
- The Prohibited List - World Anti-Doping Agency - accessed 2026-05-15
Used for athlete-facing WADA risk and peptide-class restrictions.
- Peptide therapeutics: current status and future directions - PubMed / Nature Reviews Drug Discovery - accessed 2026-05-15
Used for broad peptide-therapeutics background and evidence framing.
Personalized peptide routing
Find the right path for GHRP-6.
Take the quiz before choosing a compound, vendor, or PDF. We match your goal, experience, budget, and monitoring comfort to the next best step in the funnel.
- Goal-matched compound and protocol recommendations.
- Budget and sourcing filters before you leave the site.
- PDF unlocks shown after your personalized result.